We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Genetic Test Improves Prognosis for Esophageal Cancer

By LabMedica International staff writers
Posted on 13 Jul 2014
The genetic basis of why some people with a serious complication of acid reflux known as Barrett's esophagus go on to develop esophageal cancer has been determined. More...


A novel noninvasive test could detect esophageal cancer much earlier, thereby improving the prognosis of what is currently a cancer with a poor survival rate. Esophageal cancer makes up about 1% of all cancers diagnosed in the USA, where estimates suggest that in 2014, about 18,170 people will discover they have the cancer, and about 15,450 will die of it.

A consortium of international scientists led by those at University of Cambridge (UK) and collaborating with the University of Southampton (UK) sequenced the DNA of patients with Barrett's esophagus and patients with esophageal cancer (EAC), and mapped out their genetic similarities and differences.

The team used a "non-endoscopic" test to identify high-risk Barrett's esophagus by retrieving cells from the affected part of the esophagus that could then be checked for presence of the mutated genes. The "non-endoscopic" test is called the cytosponge, or "sponge-on-a-string" test, and involves the patient swallowing a capsule containing a sponge attached to a thread. When the capsule reaches the stomach it dissolves, releasing the sponge, which collects cells from the esophagus wall as it is pulled out by the clinician or nurse.

Mutation validation was performed in a cohort of 90 EACs and 109 Barrett's esophagus biopsies, including 43 Barrett's esophagus biopsies with histopathologically confirmed high-grade dysplasia (HGD) and 66 with no dysplasia. The Access Array microfluidics polymerase chain reaction (PCR) platform (Fluidigm; South San Francisco, CA, USA) together with high-throughput sequencing (Illumina; San Diego, CA, USA) was used for targeted resequencing.

The scientists found mutations in the genes tumor protein 53 (TP53) and SMAD family member 4 (SMAD4) that offered a way of identifying patients in which Barrett's esophagus is progressing into cancer. Although the cytosponge is still under development, the investigators believe it could be used to look for mutations in TP53 and SMAD4 to identify patients with early stage esophageal cancer.

There are two types of esophageal cancer, adenocarcinoma and squamous cell carcinoma. People with Barrett's esophagus, a condition that can develop from prolonged, untreated acid reflux or heartburn have a higher risk of developing adenocarcinoma of the esophagus. Tim Underwood, MBBS, PhD, FRCS, a clinician scientist and esophageal surgeon and coauthor of the study said, “This is a landmark study into the genetic basis of why and how some people with Barrett's esophagus get esophageal cancer and others do not. It is still early, but we very much hope that this information will lead to a game-changer for a cancer with one of the worst outcomes.” The study was published on June 22, 2014, in the journal Nature Genetics.

Related Links:

University of Cambridge
University of Southampton
Fluidigm


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.